Start-ups

Short profiles

• Medicia

  Medical field: Oncology, gynaecological oncology (project focus); supportive care and
  survivorship
  Product type: Physician-governed longitudinal oncology care and federated research
  platform (software)
  Growth stage: Commercial; in production at national scale
  Team: 25 employees

  Description of product:
  A physician-governed platform for continuous longitudinal oncology care and federated research. It supports patients in the long stretches between hospital visits, captures CTCAE-graded symptoms and patient-reported outcomes, and surfaces decision-facing intelligence to the care team through physician-authored logic. Live at national scale in Singapore (approximately 40,000 patients, 40M+ records, ISO/IEC 27001 certified, MOH-approved), with active programmes at Mayo Clinic and UTMB.

  Desired project goal:
  Co-develop and validate a localised gynae-oncology care plan at Charité, demonstrating continuous monitoring and decision-facing clinical intelligence. Primary outcome: a validated care plan in a Charité cohort, as the foundation for wider deployment and joint research.

  Download short profile as PDF

• Moon Technologies Pte. Ltd.

  Medical field: Ophthalmology – ocular toxicity monitoring in ADC therapy
  Product type: Modular wearable AR ophthalmic assessment device (hardware + software). HSA Singapore Class A; EU MDR class to be confirmed.
  Growth stage: Commercial — early distributor revenue in Asia- Pacific; pre-Series A. TRL 6 / BRL 5.
  Team: 8 employees

  Description of product:
  Moon Glass is a modular wearable ophthalmic assessment platform. For this project the relevant capabilities are anterior segment (corneal) imaging, bestcorrected visual acuity, and subjective refraction — acquired by a nurse or clinical assistant in the oncology unit, at the treatment chair, producing structured digital output for remote specialist read. Critically, Glass does not change who is responsible for the read: a qualified eye care professional remains the reader of record and the authority for the dosing decision. It changes only where and by whom acquisition happens. Registered Class A with HSA Singapore, with clinical validation studies underway in Singapore, Taiwan, Australia and India.

  Desired project goal:
  Category B — joint R&D / co-development, with foreground IP shared
  between Moon and Charité/BIH. We propose to co-develop and validate an
  agent-agnostic, point-of-care ocular monitoring pathway for antibody-drug
  conjugates with ocular surface toxicity, applicable across Charité’s oncology
  portfolio.

  The Problem: Ocular surface toxicity is a class effect of ADCs, driven largely by
  the cytotoxic payload rather than the antibody target — reported in over 80%
  of patients on belantamab mafodotin, up to 61% on mirvetuximab
  soravtansine and up to 55% on tisotumab vedotin, and recurring with each
  new agent. Reported rates vary widely across the class, in part because
  monitoring methods are not standardised and are inconsistent.
  Requirements differ agent by agent, while grading is split across different
  scales such as Common Terminology Criteria for Adverse Events (CTCAE) and
  drug-specific scales. No cross-class consensus scale yet exists. Many corneal
  findings are asymptomatic, so symptom-triggered referrals under-detects.
  Furthermore, each affected agent adds recurring demand for specialist
  ophthalmic assessment scheduled around oncology infusions. This creates a
  bottleneck that compounds as more ADCs enter routine European practice.

  Download short profile as PDF

• Osteopore International

  Medical field: Neurosurgery
  Product type: Custom cranioplasty
  Growth stage: Custom Made Device under MDR 2017/745
  Team: 25 employees

  Description of product:
  Customised cranioplasty device made from bioresorbable 3D printed bio composite including polycaprolactone and beta-tricalcium phosphate.

  Desired project goal:
  Through this collaboration, we would like to generate prospective clinical data. We already have more then 80-100 cases in Asia Pacifc, and while we have some data on file, we would very much like to generate Europe-centric dataset to support our launch in the region. In this process, we would also like to build up our potential KOLs whom we can work with, to speak about the product and if the opportunity is timely, we could also do joint-development of new products.

  Download short profile as PDF

• Qritive Pte Ltd

  Medical field: Oncology/Pathology
  Product type: AI/Software-based Diagnostic Tool — specifically Software as a Medical Device (SaMD) / Clinical Decision Support Software
  Growth stage: Commercials, Products deployed live for customers
  Team: 9 employees

  Description of product:
  AI models which can predict patient survival probability and PD-L1 tumor proportion score directly from standard H&E slides. By eliminating the need for immunohistochemistry (IHC) for low-risk cases, these models offer a cost-effective screening alternative for patients who cannot afford advanced testing or for healthcare settings where IHC is unavailable.

  Desired project goal:
  This study evaluates whether an AI model trained on multiplex immunofluorescence (mIF) can extract prognostic morphological features directly from H&E images for patient screening, using Charité's paired H&E/mIF NSCLC cohort (Schallenberg et al., 1,168 patients) where both modalities were generated from the same physical tissue sections.

  Download short profile as PDF